2023 World Conference on Lung Cancer (Posters)-EP13.07. A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer

EP13.07. A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to investigate the efficacy and safety of combining sintilimab with anlotinib and albumin-bound paclitaxel as a second-line or later therapy for patients with extensive-disease small cell lung cancer (ED-SCLC). ED-SCLC is a type of lung cancer characterized by rapid growth, drug resistance, and early metastasis.<br /><br />The study enrolled 30 patients, of which 23 were evaluated. The primary endpoint was the objective response rate (ORR), which was found to be 60.9%. This included 14 cases of partial response (PR), 3 cases of stable disease (SD), and 6 cases of progressive disease (PD). The disease control rate (DCR) was 73.9%. The median duration of response (DOR) was 6.8 months, with a median time to response (TTR) of 1.5 months.<br /><br />The median progression-free survival (PFS) was 5.91 months, and the 6-month PFS rate was 48.6%. The median overall survival (OS) was 13.2 months, with 12- and 18-month PFS rates of 58.8% and 46.3%, respectively.<br /><br />The safety profile of the treatment combination was manageable, with no unexpected adverse events reported. Treatment-related adverse events (AEs) were observed in all patients, with 5 cases of grade 3 AEs leading to drug discontinuation, but no deaths were reported. Immunotherapy-related adverse events (irAEs) were observed in 91.3% of patients.<br /><br />In conclusion, the study found that combining sintilimab with anlotinib and albumin-bound paclitaxel showed significant clinical activity and a manageable safety profile as a second-line or later therapy for patients with ED-SCLC. Further follow-up is needed to assess the long-term efficacy of this treatment combination.

Asset Subtitle

Zhehai Wang

Meta Tag

Speaker Zhehai Wang

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

sintilimab

anlotinib

albumin-bound paclitaxel

extensive-disease small cell lung cancer

efficacy

safety

second-line therapy

objective response rate

disease control rate

progression-free survival